,22 Thus, we investigated the utility of R848 (Resiquimod), an innate immune agonist of the TLR7/8 pathway that is commonly used in cancer immunotherapy, in enhancing the immune-stimulatory effects of CD40 agonism. This evidence concerns the gene CD40 and cancer.